Related Experiment Video

Updated: Aug 18, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without

J Mercieca¹, E Matutes, E Emmett

¹Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, London, UK.

British Journal of Haematology

|May 1, 1996

Abstract:

We treated 26 patients with hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine, including nine with abdominal lymphadenopathy and of whom two had HCL-variant; 18 were previously treated. The overall response in 23 evaluable HCL patients was 100% with 87% complete remission (CR). The CR rate was 57% in patients with abdominal lymphadenopathy. Neither of the patients with HCL-variant achieved CR. Of four patients who had become refractory to 2'-deoxycoformycin, two achieved CR and one partial remission (PR). The lower response in HCL with abdominal lymphadenopathy supports the view that this represents a more resistant form of the disease.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Articles linked to this work by shared authors, journal, and citation graph.

Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.

Nature genetics·1997

G-CSF mobilization of haemopoietic cell populations in SCID mice engrafted with human leukaemia.

Bone marrow transplantation·1997

The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study.

British journal of haematology·1997

The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia.

Leukemia·1997

Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia?

Leukemia·1997

HTLV-I and HTLV-II infections in hematologic disorder patients, cancer patients, and healthy individuals from Rio de Janeiro, Brazil.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1997

See all related articles